Companies / MRNA vs GILD
MRNA vs GILD: Moderna and Gilead Sciences
Moderna (MRNA) reported $1.9B in revenue against a -145.2% net margin, while Gilead Sciences (GILD) reported $29.4B at a 28.9% net margin, most recently.
| Metric | MRNA | GILD |
|---|---|---|
| Revenue | $1.9B | $29.4B |
| Net Income | $-2.8B | $8.5B |
| Gross Margin | 55.3% | 78.8% |
| Operating Margin | -158.1% | 34.0% |
| EPS (Diluted) | $-7.26 | $6.78 |
| Free Cash Flow | $-2.1B | $9.5B |
| Total Debt | $0.6B | $24.9B |
| P/E Ratio | n/m | 18.1× |
| P/B Ratio | 1.3× | 6.7× |
| Stock Price | $241.26 | $167.53 |
Free: last 5 years
| Fiscal year | FY2016 🔒 | FY2017 🔒 | FY2018 🔒 | FY2019 🔒 | FY2020 🔒 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| MRNA Revenue | ••••• | ••••• | ••••• | ••••• | ••••• | $18.5B | $19.3B | $6.8B | $3.2B | $1.9B |
| GILD Revenue | ••••• | ••••• | ••••• | ••••• | ••••• | $27.3B | $27.3B | $27.1B | $28.8B | $29.4B |